23andMe Stock

23andme.comHealthcareFounded: 2006Funding to Date: $876.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Register for Details

For more details on financing and valuation for 23andMe, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for 23andMe.

Register Today

23andMe investors also invested in these private companies

Team

Management Team

Steve Schoch
CFO
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Anne Wojcicki
CEO & Co-Founder
Fred Kohler
Vice President, People
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Mike Polcari
Vice President & Chief Architect

Board Members

Patrick Chung
Xfund
Roelof Botha
Sequoia Capital
Anne Wojcicki
23andMe
Neal Mohan
23andMe
Richard Scheller, Ph.D.
Self

Other companies like 23andMe in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.
Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.